Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4205.70 +0.8% SILVER 57.78 +1.1% COPPER 6.60 +0.7% OIL 95.97 −2.0% PALLADIUM 1127.25 −0.1% OMI 0.250 +0.0% BUFF 0.810 +3.9% FEO 0.650 +0.0% LIB 0.750 +4.2% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.540 +3.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.340 +0.0% SLG 5.50 −3.7% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.550 −1.8% PWRO 0.025 +0.0% GOLD 4205.70 +0.8% SILVER 57.78 +1.1% COPPER 6.60 +0.7% OIL 95.97 −2.0% PALLADIUM 1127.25 −0.1% OMI 0.250 +0.0% BUFF 0.810 +3.9% FEO 0.650 +0.0% LIB 0.750 +4.2% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.540 +3.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.340 +0.0% SLG 5.50 −3.7% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.550 −1.8% PWRO 0.025 +0.0%
Production / Operations

Terumo Launches SurTract(TM) Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR(TM) Passive Safety Technology

By The Northwire Desk — AI Analysis Jan 06, 2026 · 08:29 4543 · None None
4543 · Price

Executive Summary

  • Terumo Medical Corporation announced the U.S. launch of its new SurTract™ Safety Syringe, incorporating Roncadelle Operations’ SafeR® passive safety technology.
  • The syringe features an automatic needle‑retraction mechanism, customizable blunt needles, reduced medical waste, and low dead‑space design to minimize medication waste.
  • Distribution will begin across hospitals, clinics, and emergency‑care settings in Q1 2026.

Key Details

  • Product: SurTract™ Safety Syringe – a retractable safety hypodermic syringe powered by SafeR® passive safety technology.
  • Technology: SafeR® provides fully passive, automatic needle retraction into the plunger immediately after use, reducing needle‑stick injuries and improving patient comfort.
  • Key Benefits:
  • Customizable blunt‑needle selection for optimal clinical use.
  • Elimination of external plastic safety sheath → less medical waste.
  • Low dead‑space design → reduced medication waste.
  • Launch Timeline: Distribution in the United States to begin in the first quarter of 2026 across hospitals, clinics, and emergency‑care settings.
  • Quotes:
  • Bob Klock, Vice President, Terumo Medical Corporation – “The SurTract Syringe combines Terumo's trusted clinical know‑how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections.”
  • Dr. Fred Metzmann, Chief Business Development Officer, Roncadelle Operations – “Terumo has significantly advanced injection safety with the integration of our SafeR technology… delivering a next‑generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.”

Notable Quotes

  • “It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal.” – Bob Klock, VP, Terumo Medical Corporation
  • “Together, we are delivering a next‑generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.” – Dr. Fred Metzmann, Roncadelle Operations
Read the original news release →

More from None

May 14, 2026 · 08:00

Strategic Integration of OrganOx Signals Portfolio Expansion

Management Feb 19, 2026 · 04:35

Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships

Other Oct 30, 2025 · 08:00

OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation

M&A / Property Oct 28, 2025 · 08:00

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Financings